Takahashi H, Koike T, Yoshida N, Kitahara O, Hanano M, Shibata A, Aoki N
Am J Hematol. 1986 Oct;23(2):153-66. doi: 10.1002/ajh.2830230210.
We performed a hemostatic evaluation in detail in a patient with suspected amyloidosis who was suffering from several bleeding episodes. He had a shortened euglobulin clot lysis time, decreased alpha 2-plasmin inhibitor (alpha 2-PI), decreased plasminogen, elevated tissue-type plasminogen activator (t-PA), elevated plasmin-alpha 2-PI complex, and decreased ratio of ristocetin cofactor to von Willebrand factor (vWF) antigen. Fibrinogen and fibrin/fibrinogen degradation products levels fluctuated, with abnormal values on several occasions. On crossed immunoelectrophoresis, plasmin-alpha 2-PI complex and vWF fragment were demonstrated in the patient plasma. These abnormal findings and bleeding symptoms improved following the administration of tranexamic acid. Discontinuation of tranexamic acid resulted in deterioration of these parameters. These observations indicate that pathologic fibrinolysis (continuous intravascular plasmin generation) characterized by the consumption of alpha 2-PI and plasminogen, formation of plasmin-alpha 2-PI complex, and fragmentation of vWF contributed to the bleeding in this patient. It is important to recognize excessive fibrinolysis as the underlying cause of bleeding in these patients, since specific treatment with antifibrinolytic agents is effective in controlling the bleeding.
我们对一名疑似淀粉样变性且有多次出血发作的患者进行了详细的止血评估。他的优球蛋白凝块溶解时间缩短,α2-纤溶酶抑制剂(α2-PI)降低,纤溶酶原降低,组织型纤溶酶原激活剂(t-PA)升高,纤溶酶-α2-PI复合物升高,瑞斯托霉素辅因子与血管性血友病因子(vWF)抗原的比值降低。纤维蛋白原和纤维蛋白/纤维蛋白原降解产物水平波动,有几次出现异常值。在交叉免疫电泳中,患者血浆中显示出纤溶酶-α2-PI复合物和vWF片段。给予氨甲环酸后,这些异常发现和出血症状得到改善。停用氨甲环酸导致这些参数恶化。这些观察结果表明,以α2-PI和纤溶酶原消耗、纤溶酶-α2-PI复合物形成以及vWF片段化为特征的病理性纤溶(持续血管内纤溶酶生成)导致了该患者的出血。认识到过度纤溶是这些患者出血的潜在原因很重要,因为用抗纤溶药物进行特异性治疗对控制出血有效。